Dr.Kenneth Preston

Dr.Kenneth Preston Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Dr.Kenneth Preston, Hospital, Bentonville, AR.

Hormonal imbalances are among the most common causes of gynecomastia, especially during puberty. Once hormone levels nor...
06/11/2025

Hormonal imbalances are among the most common causes of gynecomastia, especially during puberty. Once hormone levels normalize, gynecomastia usually regresses, though not always. Other factors can also trigger breast growth in men. These include intake of female hormones (for example, through beer consumption or certain meats), the natural decline of testosterone levels with age, use of anabolic steroids or hair-loss medications, and of course genetics. While excess weight can make the appearance more pronounced, it isn’t the root cause. Men’s breasts can develop in both lean and overweight individuals—and they can look very different from one another.

GynecomastiaGynecomastia is a benign enlargement of the male breast gland. It can occur on one side or both sides. Gynec...
06/11/2025

Gynecomastia
Gynecomastia is a benign enlargement of the male breast gland. It can occur on one side or both sides. Gynecomastia should be distinguished from so-called pseudogynecomastia (lipomastia), which is caused by an excess accumulation of fatty tissue in the chest area due to severe overweight. Gynecomastia isn’t always pathological—it can also occur naturally during certain life stages in boys or men.

It's such a nice day!!🌤
09/05/2024

It's such a nice day!!🌤

05/28/2024

Fungal Diseases
Fungi include a wide range of organisms, such as mushrooms, molds, and yeast, that are common outdoors in water, soil and air; indoors on surfaces; and on our skin and inside our bodies. Mold can worsen breathing problems in people with allergies or asthma, while various types of fungi can infect nails and cause skin rashes.
Some fungal infections are more common in people with weakened immune systems or hospitalized individuals, while other fungal infections can infect anyone, including otherwise healthy people. There are only four classes of antifungal drugs, and fungal strains resistant to these drugs are emerging. Currently, there are no approved vaccines to prevent fungal infections.
NIAID conducts and supports basic research to understand how fungal pathogens cause disease and how the immune system responds to infection. NIAID is also conducting and supporting the science to find new ways to diagnose, treat and prevent fungal infections.

Positive outcomes following Autologous Matrix-Induced Chondrogenesis (AMIC) in the treatment of retropatellar chondral l...
05/28/2024

Positive outcomes following Autologous Matrix-Induced Chondrogenesis (AMIC) in the treatment of retropatellar chondral lesions: a retrospective analysis of a patient registry
Abstract
Background: The patellofemoral joint is a challenging environment for treating chondral defects. Among the surgical options for the treatment of chondral defects, the single-stage Autologous Matrix-Induced Chondrogenesis (AMIC) procedure uses a porcine collagen I/III membrane to enhance bone-marrow stimulation. However, longer term outcomes data are rare for this specific indication. In order to provide real-world information, an ongoing registry has been established to record patient data and outcomes when AMIC is used to treat chondral and osteochondral lesions.
Methods: Patient data were retrieved from an ongoing, prospective, multisite registry of patients who had undergone AMIC treatment of chondral defects. We identified 64 patients who had undergone AMIC for patellofemoral chondral defects and for whom pre-operative and at least 1 post-operative score were available were included in this retrospective data analysis. Outcomes were assessed via the KOOS, VAS pain, and the Lysholm scores. Outcomes at the post-operative time-points were analysed using a factorial ANOVA with post-hoc testing while linear regression was used to assess associations between the change in the Lysholm score and lesion size.
Results: There was a significant improvement in Lysholm, VAS pain, and KOOS scores from pre-operative to the 1st year post-operative (p < 0.001), and this was maintained during the follow-up.
Conclusions: The forces exerted on the patellofemoral joint make this a challenging scenario for chondral repair. Our data demonstrates that the AMIC procedure with a collagen I/III membrane is an effective treatment for retropatellar cartilage lesions, and provides reliable results, with decreased pain and improved function. Importantly, these improvements were maintained through the follow-up period.

05/28/2024

How can you mend a broken heart? Or repair a damaged liver, kidney, or knee? NIH-funded scientists are exploring innovative ways to fix faulty organs and tissues or even grow new ones. This type of research is called tissue engineering. Exciting advances continue to emerge in this fast-moving field.
Tissue engineering could allow doctors to repair or replace worn-out tissues and organs with living, working parts. Most important, tissue engineering might help some of the 120,000 people on the waitlist to receive donated kidneys, livers, or other organs.
Doctors have long used tissue-engineered skin to heal severe burns or other injuries. But most tissue engineering methods are still experimental. They’ve been tested only in laboratory dishes and sometimes in animals, but only a few new approaches have been tested in people. Several clinical studies (involving human volunteers) are in the early stages of testing newly developed tissues.
“With this approach, scientists are combining engineering and biology to restore a damaged organ or tissue, whether it’s been damaged by disease or injury or something else,” says Dr. Martha Lundberg, an NIH expert in heart-related tissue engineering.
Some scientists are creating special net-like structures, or scaffolds, in desired shapes and then coaxing cells to grow within them. Some use a mixture of natural substances called growth factors, which direct cells to grow and develop in certain ways.
“Other scientists are using different 3-D bioprinting technologies—some are like fancy inkjet printers—to create new tissues or organs,” Lundberg says. They’ve printed 3-D kidneys and other organs that look like the real thing. But while most of these printed body parts have the right shape, they’re not fully functional.
“Scientists haven’t yet figured out how to print an organ that includes the correct blood vessel patterns, nerve connections, and other components that come together in a mature organ,” Lundberg says. “When creating a new organ, if it can perform the right job and functions, it may not need to look like the real thing.”
Many tissue engineering methods use stem cells, which can be nudged to turn into different cell types. One research team guided human stem cells to become a 3-D structure that can respond to light. The method might one day lead to new therapies for eye disorders. Other stem cell approaches may lead to improved treatment for spinal cord injuries, diabetes, and more.
Another approach, called decellularization, involves removing all the cells from an organ. What’s left behind is a thin, pale framework that contains the organ’s natural structural proteins, including the pathways for tiny blood vessels and nerves. By infusing new cells into this mesh-like matrix, some researchers have successfully created working animal kidneys, livers, hearts, lungs, and other organs.
The decellularization technique was used by Dr. Martin Yarmush and his colleagues to create a functional rat liver that included a network of working blood vessels. Yarmush is a biomedical engineer at Rutgers University and the Massachusetts General Hospital. The engineered livers his team created were kept alive in the laboratory for days and functioned for several hours after transplantation into rats. The researchers are now working to help those transplanted livers survive even longer. They’re also scaling up the methods to create a decellularized human liver that can be repopulated with functional cells.
“A parallel effort we are pursuing involves taking a donated organ that is not considered transplantable for a particular reason, and then using a reconditioning solution and perhaps even stem cells to revitalize the organ so it becomes transplantable,” Yarmush says.
Other researchers are working to repair damaged body parts that are still in the body. At the University of Washington in Seattle, Dr. Charles Murry and colleagues are searching for ways to fix injured hearts. One of their latest studies used human stem cells to repair damaged hearts in monkeys. The stem cells were coaxed to become early-stage heart cells, which were then infused near the heart injury.
The new cells made their way into the damaged heart muscle and organized into muscle fibers in all of the treated monkeys. The infused stem cells replaced nearly half of the damaged heart tissue and began beating in sync with the heart. Still, the scientists note they need years of research before this type of therapy might be tried in people.
Some methods are already being tested in humans. Dr. Martha Murray, a surgeon at Boston Children’s Hospital, is exploring new ways to heal a common knee injury known as a torn ACL (anterior cruciate ligament). Athletes who do a lot of twisting and turning, as in basketball or soccer, are at risk for damaging the ACL.
“Typical treatment today, called ACL reconstruction, works well, and it gets patients back to the playing field at a relatively high rate,” Murray says. But the surgery involves removing a piece of tendon from elsewhere in the body and using that to replace the ACL. “So it involves making 2 injuries that the body has to heal from. And even with this treatment, patients still develop arthritis in the knee 15 to 20 years later,” Murray adds. “We wanted to find a better therapy—something less invasive.”
After testing several biomaterials, Murray’s team found that stitching a bioengineered sponge between the torn ends of an injured ACL allows blood to clot and collect around the damaged ligament. Because blood naturally contains stem cells and growth factors, the blood-soaked sponge acts as a “bridge” that encourages ACL healing. The sponge is made of some of the same proteins normally found in ligaments, and it dissolves after a few weeks.
Studies in large animals showed that the bioengineered sponge was much less likely to lead to arthritis, and it healed ACL injuries as well as standard reconstruction surgery. The U.S. Food and Drug Administration recently approved human safety testing of the sponge in 10 people with ACL injuries.
Metal, plastic, and other non-biological devices can also replace or enhance malfunctioning body parts. One promising possibility still in development is an artificial kidney that could be implanted in the body and used in place of dialysis to treat end-stage kidney disease. Scientists are also studying a synthetic glue modeled after a natural adhesive that might help to repair tissues in the body.

Fixing Flawed Body PartsEngineering New Tissues and Organs
04/30/2024

Fixing Flawed Body Parts
Engineering New Tissues and Organs

Researchers gained insights into how lizards like this green anole grow back their tails.
04/30/2024

Researchers gained insights into how lizards like this green anole grow back their tails.

Lizard tails give clues to cartilage formationMany lizards, such as the green anole, have the ability to detach and regr...
04/30/2024

Lizard tails give clues to cartilage formation
Many lizards, such as the green anole, have the ability to detach and regrow their tails, which helps them escape the grasp of predators. But the new tail’s main structural component is made of cartilage rather than the bone that was in the original tail. The regrown lizard tail also includes tissues like muscle, nerves, and blood vessels.
To learn more about cartilage creation, a research team led by Dr. Thomas Lozito at the University of Southern California examined cellular and molecular details of limb regeneration in the anole lizard. They used a technique called single-cell RNA sequencing to determine which types of cells were present at different time points after tail loss in lizards, and which types of genes were activated. Their results were reported in Nature Communications on August 10, 2023.
The scientists gained new insights into two types of cells, called fibroblasts and phagocytes, that are essential to forming new cartilage in the regrowing tail. Fibroblasts are a type of connective tissue cell. They make and secrete collagen and other proteins that help to maintain the structure of tissues. Analyses revealed different subsets of fibroblasts that played different roles in forming cartilage during the 28 days after tail loss.
Phagocytes are a type of immune cell that protects the body by gobbling up bacteria, foreign particles, and dead or dying cells. Phagocytes and other immune cells are known to congregate at injured sites. Tail regrowth involved distinct locations for different phagocytes. Factors secreted by certain phagocytes proved critical for signaling fibroblasts to build new cartilage. One particular type of phagocyte, called a septoclast, was especially important for regrowing lizard tails.
To clarify the role of septoclasts, the researchers isolated these cells from lizard tails and transferred the factors they secreted into lizards that had an amputated leg. Lizard legs, like mammal limbs, do not naturally regrow when injured. Rather, they tend to form fibrous and scar tissues, which inhibit regrowth. The scientists found that factors from septoclasts could suppress scarring in severed lizard limbs and enable formation of new cartilage.
The researchers also identified a well-known signaling pathway, called Hedgehog, that is crucial for cartilage formation. Lizards treated with a drug that blocks Hedgehog regrew tails that were normal length but lacked cartilage.
“Those two cell types working together laid the foundation for the beginning of the regenerative process,” Lozito says. “This represents an important step, because we need to understand the process in great detail before we can try to recreate it in mammals.

AmB (blue) molecules form a molecular “sponge” that captures sterols like cholesterol and ergosterol (dotted) from cell ...
04/30/2024

AmB (blue) molecules form a molecular “sponge” that captures sterols like cholesterol and ergosterol (dotted) from cell membranes. This atomic level understanding of how it works yielded a breakthrough kidney-sparing antifungal agent.

04/30/2024

The team discovered that AmB does the same thing to cholesterol in human cells, causing the damage observed in kidneys. In a new study, funded in part by NIH, the scientists altered AmB to better grab ergosterol while leaving cholesterol intact. Their results were published on November 8, 2023, in Nature.
The researchers first used atomic-level imaging to understand the structure of AmB bound to both ergosterol and cholesterol. Based on this information, they altered the structure of AmB so that it could no longer bind to cholesterol, but maintained its affinity for ergosterol.
The new compound was virtually non-toxic when tested in cells and mice, but it was less potent than AmB because it removed ergosterol from fungal cell membranes less rapidly. This gave the fungal cells time to produce enough extra ergosterol to survive.
To improve efficacy, the researchers made another tweak to the structure so that it pulled ergosterol from fungal cell membranes more quickly. The resulting compound, called AM-2-19, drew ergosterol from fungal cells rapidly but left cholesterol unaffected.
AM-2-19 proved to be safe when given in high doses to human cells and mice. Crucially, it was also as or more effective than AmB against more than 500 strains of pathogenic fungi. When tested against several potentially deadly fungal pathogens in mice, including members of the Candida, Aspergillus, and Rhizopus families, AM-2-19 eradicated several strains entirely at high doses.
“This work is a demonstration that, by going deep into the fundamental science, you can take a billion-year head start from nature and turn it into something that hopefully is going to have a big impact on human health,” Burke says. “We are very excited about the potential we are seeing, although clinical study is needed to see if this potential translates to people.”
AM-2-19 has been licensed to Sfunga Therapeutics and recently entered a phase 1 clinical trial.

Address

Bentonville, AR
72712

Alerts

Be the first to know and let us send you an email when Dr.Kenneth Preston posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr.Kenneth Preston:

Share